Empfehlungen zur kalkulierten parenteralen Initialtherapie ...

Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2010
Tagen nach dem letzten Patientenkontakt
(www.rki.de/cln_151/nn_468086/DE/Content/Infekt/EpidBull/Archiv/2002/30__02ausschnitte/30__02-21__STIKO__HIBspezProph.html):
Erwachsene (außer
Schwangere) erhalten Rifampicin (600 mg
alle 24 Stunden für 4 Tage, p.o.); Neugeborene
bzw. Kinder erhalten Rifampicin
(10 bzw. 20 mg/kg KG alle 24 Stunden für
4 Tage, p.o.).
Addendum
In einer kürzlich veröffentlichten Meta-
Analyse wird die Wirksamkeit von adjuvantem
Dexamethason bei der bakteriellen
Meningitis verneint [30].
Literatur
1. Aronin SI, Peduzzi P, Quagliarello VJ.
Community-acquired bacterial meningitis:
risk stratification for adverse clinical
outcome and effect of antibiotic timing.
Ann Intern Med 1998;129:862-9.
2. Alcala B, Salcedo C, de la Fuente L,
Arreaza L, et al. Neisseria meningitidis
showing decreased susceptibility
to ciprofloxacin: first report in Spain. J
Antimicrob Chemother 2004;53:409.
3. Auburtin M, Wolff M, Charpentier J,
Varon E, et al. Detrimental role of de -
layed antibiotic administration and penicillin-nonsusceptible
strains in adult
in ten sive care unit patients with pneumococcal
meningitis: the PNEUMOREA
prospective multicenter study. Crit Care
Med 2006;34:2758-65.
4. Bohr V, Hansen B, Jessen O, Johnsen N,
et al. Eight hundred and seventy-five
cases of bacterial meningitis. I. Clinical
data, prognosis, and the role of specialized
hospital departments. J Infect
1983;7:21-30.
5. Durand ML, Calderwood SB, Weber DJ,
Miller SI, et al. Acute bacterial meningitis
in adults: a review of 493 episodes.
N Engl J Med 1993;328:21-8.
6. Fraser A, Gafter-Gvili A, Paul M, Leibovici
L. Antibiotics for preventing meningococcal
infections. Cochrane Database
Syst Rev 2006:CD004785.
7. Hasbun R, Abrahams J, Jekel J, Quagliarello
VJ. Computed tomography of the
head before lumbar puncture in adults
with suspected meningitis. N Engl J Med
2001;345:1727-33.
8. De Gans J, van de Beek D. Dexamethasone
in adults with bacterial meningitis.
N Engl J Med 2002;347:1549-56.
9. Klugman KP, Friedland IR, Bradley JS.
Bactericidal activity against cephalosporin-resistant
Streptococcus pneumoniae
in cerebrospinal fluid of children with
acute bacterial meningitis. Antimicrob
Agents Chemother 1995;39:1988-92.
10. Kommission “Leitlinien der Deutschen
Gesellschaft für Neurologie”. Leitlinien
für Diagnostik und Therapie in der Neurologie,
4. überarbeitete Auflage. Georg
Thieme Verlag, Stuttgart - New York
2008.
11. Lebel MH, McCracken GH Jr. Delayed
cerebrospinal fluid sterilization and
adverse outcome of bacterial meningitis
in infants and children. Pediatrics 1989;
83:161-7.
12. Marcos MA, Martínez E, Almela M,
Mensa J, et al. New rapid antigen test
for diagnosis of pneumococcal meningitis.
Lancet 2001;357:1499-500.
13. Molyneux EM, Walsh AL, Forsyth H,
Tembo M, et al. Dexamethasone treatment
in childhood bacterial meningitis
in Malawi: a randomised controlled trial.
Lancet 2002;360:211-8.
14. Nau R, Brück W. Neuronal injury in bacterial
meningitis: mechanisms and implications
for therapy. Trends Neurosci
2002;25:38-45.
15. Peltola H, Anttila M, Renkonen OV,
the Finnish Study Group. Randomised
comparison of chloramphenicol, ampicillin,
cefotaxime, and ceftriaxone for
childhood bacterial meningitis. Lancet
1989;1(8650):1281-7.
16. Prange H, Bitsch A (Hrsg.). Infektionserkrankungen
des Zentralnervensystems,
2.Auflage. Wissenschaftliche Verlagsgesellschaft,
Stuttgart 2001.
17. Prasad K, Singh MB. Corticosteroids
for managing tuberculous meningitis.
Cochrane Database Syst Rev 2008:
CD002244.
18. Quagliarello VJ, Scheld WM. Treatment
of bacterial meningitis. N Engl J Med
1997;336:708-16.
19. Reiber H, Lange P. Quantification of
virus-specific antibodies in cerebrospinal
fluid and serum: sensitive and specific
detection of antibody synthesis in brain.
Clin Chem 1991;37:1153-60.
20. Rupprecht TA, Pfister HW. Clinical experience
with linezolid for the treatment
of central nervous system infections. Eur
J Neurol 2005;12:536-42.
21. Scarborough M, Gordon SB, Whitty CJ,
French N, et al. Corticosteroids for bacterial
meningitis in adults in sub-Saharan
Africa. N Engl J Med 2007;357:
2441-50.
22. Scheld WM, Dacey RG, Winn HR, Welsh
JE, et al. Cerebrospinal fluid outflow
resistance in rabbits with experimental
meningitis: alterations with penicillin
and methylprednisolone. J Clin Invest
1980;66:243-53.
23. Scholz H, Hofmann T, Noack R, Edwards
DJ, et al. Prospective comparison of ceftriaxone
and cefotaxime for the shortterm
treatment of bacterial meningitis in
children. Chemotherapy 1998;44:142-7.
24. Schuchat A, Robinson K, Wenger JD,
Harrison LH, et al. Bacterial meningitis
in the United States in 1995. Active
Surveillance Team. N Engl J Med 1997;
337:970-6.
25. Schultz BR, Allen CH, Kaplan SL. Corticosteroids
for acute bacterial meningitis.
Ann Emerg Med 2009;54:136-7.
26. Singhal S, Purnapatre KP, Kalia V, et al.
Ciprofloxacin-resistant Neisseria meningitidis,
Delhi, India. Emerg Infect Dis
2007;13:1614-6.
27. Skoczynska A, Alonso JM, Taha MK.
Ciprofloxacin resistance in Neisseria
meningitidis, France. Emerg Infect Dis
2008;14:1322-3.
28. Thwaites GE, Nguyen DB, Nguyen HD,
Hoang TQ, et al. Dexamethasone for
the treatment of tuberculous meningitis
in adolescents and adults. N Engl J Med
2004;351:1741-51.
29. Van de Beek D, de Gans J, McIntyre P,
Prasad K. Corticosteroids for acute bacterial
meningitis. Cochrane Database
Syst Rev 2007:CD004405.
30. Van de Beek, Farrar JJ, de Gans J, Mai
NT, et al. Adjundive dexamethasone in
bacterial meningitis: a meta-analysis of
individual patient data. Lancet Neurol
2010;9:254-63.
31. Viladrich PF, Gudiol F, Linares J, Pallarés
R, et al. Evaluation of vancomycin for
therapy of adult pneumococcal meningitis.
Antimicrob Agents Chemother
1991;35:2467-72.
32. Ziai WC, Lewin JJ 3rd. Improving the
role of intraventricular antimicrobial
agents in the management of meningitis.
Curr Opin Neurol 2009;22:277-82.
77